AtheroGenics Drops AGIX-4207 After Failed Rheumatoid Arthritis Phase II Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Placebo yielded a greater ACR 20 response rate than any of three AGIX-4207 dosing arms in the Phase II trial. The company will turn to second-generation compounds that are part of its vascular protectant program.
You may also be interested in...
Madrigal’s FDA Approval In MASH Ends Years Of Industry Frustration
As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).
No More NASHing Of Teeth: Madrigal’s Resmetirom Approval Ends Years Of Industry Frustration
US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.
Publisher’s Spotlight: The Citeline Awards Are Open For Entries!
Recognize your clinical research team, excellence in patient recruitment, technology initiatives, partnerships, diversity and inclusion efforts and more. Enter now to avoid the late submission fees.